Following the "Dogs of the Dow" strategy is one of the simplest dividend methods for beating the market. Over the coming year, I'll track the Dogs' performance and keep you abreast of news affecting these companies.
"Dogs of the Dow" refers to an investing strategy that buys and holds equal dollar amounts of the 10 best-yielding dividend stocks of the Dow Jones Industrial Average
High-yield portfolios are often dismissed as inferior to their growth counterparts for various reasons:
- Many people fear that increasing dividend yields mean lower portfolio returns.
- Others believe that dividend payments mean management believes the business is done growing.
Evidence compiled by Tweedy Browne refutes these beliefs. Research shows that portfolios of high-yield dividend stocks outperform lower-yielding portfolios and the market in general. In fact, a study by noted finance professor Jeremy Siegel found that over 45 years, the highest-yielding 20% of S&P 500 stocks outperformed the S&P 500 by three times! The highest-yielding stocks turned a $1,000 investment in 1957 into $462,750 by 2002, compared with $130,768 if the same money was invested in the index.
The Dogs of the Dow returned 12.3% in 2011, which beat the Dow's return of 5.5%.
Check out the 2012 Dogs of the Dow performance so far:
|Johnson & Johnson||3.48%||$65.58||(0.03%)|
Procter & Gamble
|Dow Jones Industrial Average||3.63%|
|Dogs of the Dow||2.06%|
|Dogs Return vs. Dow (percentage points)||(1.56%)|
Source: S&P Capital IQ as of Jan 27.
Since my last report, the Dow Jones Industrial Average fell 0.47%. The Dogs of the Dow fell more than the Dow, moving from outperforming the market by 1.6 percentage points to a 1.56-point disadvantage.
Earnings and news
Besides Verizon and AT&T, three other Dogs reported earnings this week.
- DuPont and Johnson & Johnson both reported earnings on Tuesday, and both missed analyst expectations.
- Procter & Gamble reported earnings on Friday and also missed analyst expectations.
- Pfizer reports earnings on Tuesday. Analysts expect earnings per share of $0.47 and revenue of $16.61 billion.
- Merck reports earnings on Thursday. Analysts expect earnings per share of $0.95 and revenue of $12.53 billion.
Consider these 10 tickers along with the 11 names from a new free report from The Motley Fool's expert analysts called "11 Rock-Solid Dividend Stocks." Get instant access to the names of these 11 dividend stocks for free.
Dan Dzombak holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Intel and Johnson & Johnson and has bought calls on Intel. Motley Fool newsletter services have recommended buying shares of Procter & Gamble, Pfizer, Intel, and Johnson & Johnson, creating a diagonal call position in Johnson & Johnson, and creating a bull call spread position in Intel. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.